Thursday, August 30, 2012
A University of California, San Diego team has developed a genetic method to prevent
embryonic stem cell therapies from forming cancerous teratomas following
transplantation.1 The method was safe in mice, although questions remain
about whether the genetic modifications will raise safety and regulatory
concerns in patients.
Xu said his team plans to determine
whether the strategy can eliminate the risk of teratomas during hESC-based
therapy for human diseases such as type 1 diabetes.
Martz, L. SciBX 5(34); doi:10.138/scibx.2012.890
Published online Aug. 30, 2012
1. Rong, Z. et al. J.
Biol. Chem.; published online Aug. 4, 2012; doi:10.1074/jbc.M112.383810
Contact: Yang Xu, University of California, San Diego, La Jolla, Calif.
2. Schuldiner, M. et
al. Stem Cells 21, 257-265 (2003)
3. Cheng, F. et al.
Biomaterials 33, 3195-3204 (2012)
AND INSTITUTIONS MENTIONED
Advanced Cell Technology Inc. (OTCBB:ACTC), Santa Monica, Calif.
Baylor College of Medicine, Houston, Texas
The Hebrew University of Jerusalem, Jerusalem, Israel
(SIX:ROG; OTCQX:RHHBY), Basel, Switzerland
Sun Yat-Sen University, Guangzhou, China
University of California, San Diego, La Jolla, Calif.